Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Emisphere Technologies/J Biologics

Executive Summary

Firms collaborating on an oral Factor IX formulation to treat hemophilia B. Under the agreement, Hawthorne, N.Y.-based Emisphere will provide its Oral Delivery System in return for funding from New York City-based J. ODS encapsulates therapeutic products in amino acid-based microspheres that allow the drug to enter the bloodstream unchanged from its passage through the gastrointestinal tract. J is a private, for-profit organization that supports R&D efforts related to hemophilia and blood disorders. The Factor IX is being provided under a subcontract with the American Red Cross.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS021514

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel